Recent Updates
Recently added Catalysts
Trending News :
The freshest biotech headlines moving stocks right now, newest first.
Autonomix Announces Reverse Stock Split
AMIX ▼ 6.38%
CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
COSM ▼ 11.92%
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training
ZEPP ▼ 7.12%CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CRVO ▲ 11.29%
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
CVKD ▲ 12.90%
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI ▼ 18.97%
Upcoming Catalysts That Could Move the Market
Cytisinicline, developed by Achieve Life Sciences (Read More)
Felzartamab is a fully human IgG1 anti-CD38 monocl (Read More)
Felzartamab, an investigational anti-CD38 monoclon (Read More)
Liraltagene autoleucel (lira-cel) is an innovative (Read More)
Alpha-lactalbumin (aLA) vaccine, developed by Anix (Read More)
Telomir-1 (Telomir-Zn) is a preclinical-stage smal (Read More)
ZORYVE (roflumilast) cream 0.3% is FDA approved fo (Read More)
LNTH-2501 (Ga-68 edotreotide), developed by Lanthe (Read More)
Prelude Therapeutics' KAT6A degrader program is cu (Read More)
Bempikibart (ADX-914) is a subcutaneous biologic I (Read More)
Latest Stocks News :
QUREuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
uniQure has announced preliminary data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. The initial results show that three out of six patients experienced significant reductions in seizures, while the remaining patients had variable responses. The treatment was well-tolerated with no serious adverse events reported, supporting further evaluation of AMT-260.
Read more →
SNYPress Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation has been approved in Japan for multiple myeloma treatment. This approval is based on the IRAKLIA phase 3 study, which showed non-inferior efficacy compared to the intravenous formulation. The new formulation aims to ease treatment burdens and improve patient convenience. Sarclisa SC is now available in combination with several standard-of-care regimens.
Read more →SNYCommuniqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé
Sanofi and HEC Paris have announced the launch of the 'Sanofi MBA Life Sciences Scholarship', aimed at supporting 10 MBA students annually. This initiative seeks to foster a new generation of leaders equipped to navigate the evolving healthcare landscape. The scholarships will cover 75% of tuition for candidates with scientific or medical backgrounds, promoting expertise in management and strategy.
Read more →
INCYIncyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Incyte Japan has announced the approval of Minjuvi® (tafasitamab) in combination with Lenalidomide for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval marks a significant advancement in treatment options for patients facing this challenging condition. The combination therapy aims to improve patient outcomes and address unmet medical needs.
Read more →
ALGNAlign Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. to Retire as Chairman and Kevin Conroy to be Appointed Chairman Effective July 1, 2026
Align Technology has announced a leadership transition within its board. C. Raymond Larkin, Jr. will retire as Chairman, and Kevin Conroy is set to take over the role effective July 1, 2026. This change marks a significant shift in the company's governance structure.
Read more →AMIXAutonomix Announces Reverse Stock Split
Autonomix Medical, Inc. announced a 1-for-21 reverse stock split effective June 24, 2026. This move will consolidate approximately 11.4 million shares into around 543,000 shares, aimed at improving stock value. The company continues to develop innovative technologies for treating nervous system diseases, particularly focusing on pain management solutions.
Read more →